Recursion Pharmaceuticals, Inc. (RXRX) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call indicates strong financial health with a cash runway extended to 2028 and reduced operating expenses. The company's partnerships, particularly with Sanofi and Roche/Genentech, are progressing well, and their AI-driven platform shows promising efficiency improvements. Despite some regulatory and strategic execution risks, the overall sentiment is positive, supported by optimistic guidance and significant partnership inflows. Given the company's small-cap status, these factors are likely to result in a positive stock price movement over the next two weeks.
Key Financial Performance
Cash Runway Extended to early 2028, reflecting disciplined execution and financial stewardship.
Pro Forma Operating Expenses Reduced by 35% year-over-year due to sharper focus on portfolio, optimizing G&A, and improving platform efficiency.
Cash Balance Ended the year with $754 million in cash.
Cash Operating Expenses (2026) Expected to be under $390 million, showcasing cost efficiency.
Partnership Inflows Achieved over $500 million in cumulative partner inflows, with $134 million from Sanofi collaboration milestones and upfront payments.
Compound Synthesis Efficiency Synthesized 90% fewer compounds (300 vs. 2,500 industry average) and achieved 2x faster timelines (17 months vs. 42 months industry average).
REC-4881 Clinical Data Achieved 43% median polyp burden reduction in Phase II study for FAP, with durable effects even off treatment.
Sanofi Collaboration Achieved fifth milestone, reflecting progress in oncology and I&I programs.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
AI-enabled clinical proof of concept with FAP: First positive proof of concept achieved for FAP, a disease with no approved therapies, showing durable and meaningful polyp burden reduction.
PI3K 1047 mutant selective program: Preclinical data shows significant tumor regression and improved tolerability compared to existing treatments. IND-enabling studies ongoing with a go/no-go decision expected in the second half of the year.
ENPP1 program: Focus on developing an oral molecule for hyperphosphatasia, a lifelong disease. IND-enabling studies ongoing with a go/no-go decision expected in the second half of the year.
Sanofi partnership: Achieved fifth milestone in collaboration with Sanofi, focusing on challenging targets in I&I and oncology. Joint portfolio includes multiple programs with potential first-in-class or best-in-class molecules.
Partnership economics: Over $500 million in total cash inflows from partnerships, with potential for over $300 million in milestones and tiered royalties per small molecule program.
Operational efficiency: Achieved a 35% reduction in pro forma operating expenses year-over-year, extending cash runway to early 2028.
AI-driven chemistry platform: Synthesizing 90% fewer compounds (300 vs. 2,500 industry average) and achieving 2x faster timelines (17 months vs. 42 months industry average).
Strategic pillars: Focused on clinical proof points, platform investment, and disciplined execution to achieve more with less.
Clinical development AI platform: Built a platform leveraging 300 million real-world patient lives, improving enrollment rates by 1.3-1.6x and reducing study startup times by up to 3 months.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Conditions: The company acknowledges the broader momentum in the AI-driven biology and chemistry sector but also notes that the industry is entering a new phase where value is defined by translating models and collaborations into real applications and measurable impact. This transition could pose challenges in maintaining competitive differentiation and delivering tangible results.
Regulatory Hurdles: The company plans to engage with the FDA for its REC-4881 program in 2026 to discuss registrational study design. Regulatory approval processes are inherently uncertain and could delay or impact the program's progress.
Supply Chain and Operational Efficiency: The company has reduced pro forma operating expenses by 35% year-over-year and extended its cash runway to early 2028. However, maintaining this level of operational efficiency while advancing multiple programs and partnerships could be challenging.
Economic Uncertainties: The company relies on partnerships and milestone payments, having achieved over $500 million in cumulative partner inflows. Economic downturns or changes in partner priorities could impact future inflows and financial stability.
Strategic Execution Risks: The company is focused on disciplined execution and outcomes-based budgeting. However, the complexity of managing a diversified portfolio, advancing AI platforms, and achieving proof points across multiple programs and partnerships could strain resources and execution capabilities.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations: The company expects to achieve additional milestones and inflows from partnerships, with over $500 million already achieved and more anticipated in the coming years. Each program has the potential for over $300 million in milestones and tiered royalties per small molecule program, with some royalties reaching double digits.
Margin Projections: The company has achieved a 35% reduction in pro forma operating expenses year-over-year and expects 2026 cash operating expenses to be under $390 million. This disciplined financial management has extended the cash runway to early 2028.
Capital Expenditures: The company is focusing on disciplined execution and outcomes-based budgeting to maximize value creation while minimizing costs. No specific capital expenditure figures were provided, but the emphasis is on efficient resource allocation.
Market Trends: The company is leveraging AI to redefine drug discovery and development, focusing on precision operations and integrating biology, chemistry, and clinical development. The broader industry momentum in AI-driven R&D is seen as a positive trend.
Business Segment Performance: The company is advancing its diversified portfolio, including AI-enabled clinical proof of concept with FAP and other programs in various stages of development. Partnerships with Sanofi and Roche/Genentech are progressing, with significant milestones achieved and more expected.
Future Financial Projections: The company has updated its cash runway guidance to early 2028, supported by disciplined financial management and expected inflows from partnerships.
Growth Expectations: The company anticipates significant growth through its diversified portfolio, partnerships, and innovative AI-driven platform. Key programs like REC-4881 and PI3K are expected to advance, with multiple catalysts anticipated over the next 18-24 months.
Strategic Plans: The company plans to engage with the FDA for REC-4881 in the first half of 2026, with additional data expected in 2027. Other programs like RBM39, PI3K, and ENPP1 are progressing, with go/no-go decisions and data updates expected in the near term. The company is also focusing on expanding its AI platform and achieving milestones with partners like Sanofi and Roche/Genentech.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the potential registrational pathway for REC-4881 and the regulatory update timeline?
A:The initial engagement with the FDA is on track for the first half of 2026. Discussions will focus on the potential design for the registrational study, patient population, and endpoints. Data on durability and polyp burden reduction, along with natural history data, will be key. Updates on patient population and dose optimization schedules are expected in the first half of 2027.
Q:Are the cost-cutting measures sustainable, and were there any one-offs in Q4?
A:The focus is on efficiency rather than cost-cutting. There were no significant one-offs in Q4. The company aims to grow its pipeline and invest in its platform while maintaining cost targets through agile capital allocation and data-driven decisions.
Q:What is the rationale behind the divestment from NVIDIA, and will there be other technology partners?
A:The divestment was part of NVIDIA's portfolio shift towards larger, on-strategy investments like supercomputers and data centers. The technical collaboration with NVIDIA continues, including work on BioHive-2 and machine learning. Recursion also has a strategic partnership with Google for cloud computing and will continue bridging tech and science.
Q:What metrics or comparisons demonstrate Recursion's improvement in clinical success or speed of development?
A:The company highlights repeatability and scalability in its platform, as seen in the Sanofi pipeline and REC-4881's clinical proof of concept. Metrics include the number of novel compounds synthesized, speed to development candidates, and reduced costs and timelines for INDs. The focus is on engineering, automation, and probabilistic approaches to drug discovery and development.
Q:Review of Unclear Management Responses
A:Management avoided directly addressing specific metrics or historical comparisons that quantitatively demonstrate improvement in clinical success or speed of development. Their responses included general statements about repeatability, scalability, and probabilistic approaches without providing detailed data or examples.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI chemistry
AI platform
ENPP
II oncology
Number
Phase monotherapy
Recursion differentiation
Recursion platform
Scorpion PIQRAY
challenge
clinic
component platform
cycle
decision
development AI
discipline
effort
foundation model
hyperglycemia
industry
interruption
machine
order molecule
pillar
platform portfolio
polyp burden
portfolio partner
program category
proof point
reduction regression
regression compound
repeatability
royalty
selective
selectivity
state
tolerability
trajectory
type
RXRX Transcript
Recursion Pharmaceuticals, Inc. (RXRX) Q4 2025 Earnings Call Transcript
Positive2-25
The earnings call indicates strong financial health with a cash runway extended to 2028 and reduced operating expenses. The company's partnerships, particularly with Sanofi and Roche/Genentech, are progressing well, and their AI-driven platform shows promising efficiency improvements. Despite some regulatory and strategic execution risks, the overall sentiment is positive, supported by optimistic guidance and significant partnership inflows. Given the company's small-cap status, these factors are likely to result in a positive stock price movement over the next two weeks.
Recursion Pharmaceuticals, Inc. (RXRX) Presents at 28th Annual Needham Growth Conference Transcript
Neutral1-22
Recursion Pharmaceuticals, Inc. (RXRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-13
Recursion Pharmaceuticals, Inc. (RXRX) Presents at Jefferies London Healthcare Conference 2025 Transcript
Neutral11-21
RXRX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
